US2019262319A1PendingUtilityA1

Novel methods for treating cancer

57
Assignee: BOSTON BIOMEDICAL INCPriority: Jan 27, 2014Filed: Oct 25, 2018Published: Aug 29, 2019
Est. expiryJan 27, 2034(~7.5 yrs left)· nominal 20-yr term from priority
Inventors:Chiang Jia LiYouzhi Li
A61P 5/14A61P 35/00A61P 43/00A61P 35/04A61P 13/12A61P 25/00A61P 13/10A61P 1/16A61P 1/04A61P 17/00A61P 15/00A61P 1/18A61P 11/00A61P 13/08G01N 33/57595G01N 33/575G01N 33/5758A61K 31/427G01N 2333/82G01N 2800/52A61K 31/404G01N 2333/912C07D 417/14G01N 33/574G01N 33/57496
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a cancer in a human subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the compound is administered to the subject at a total daily dose of about 300 mg.

Join the waitlist — get patent alerts

Track US2019262319A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.